HK1087335A1 - Survivin-derived peptides and use thereof - Google Patents

Survivin-derived peptides and use thereof

Info

Publication number
HK1087335A1
HK1087335A1 HK06107692.0A HK06107692A HK1087335A1 HK 1087335 A1 HK1087335 A1 HK 1087335A1 HK 06107692 A HK06107692 A HK 06107692A HK 1087335 A1 HK1087335 A1 HK 1087335A1
Authority
HK
Hong Kong
Prior art keywords
survivin
derived peptides
peptide
cells
class
Prior art date
Application number
HK06107692.0A
Other languages
English (en)
Inventor
Eivind Per Thor Straten
Mads Hald Andersen
Original Assignee
Survac Aps Alhambravej
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/354,090 external-priority patent/US20040210035A1/en
Application filed by Survac Aps Alhambravej filed Critical Survac Aps Alhambravej
Publication of HK1087335A1 publication Critical patent/HK1087335A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
HK06107692.0A 2003-01-30 2006-07-10 Survivin-derived peptides and use thereof HK1087335A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/354,090 US20040210035A1 (en) 2002-01-30 2003-01-30 Survivin-derived peptides and use thereof
US10/715,417 US7892559B2 (en) 2002-01-30 2003-11-19 Survivin-derived peptides and use thereof
PCT/DK2004/000062 WO2004067023A2 (en) 2003-01-30 2004-01-30 Survivin-derived peptides and use thereof

Publications (1)

Publication Number Publication Date
HK1087335A1 true HK1087335A1 (en) 2006-10-13

Family

ID=32829435

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06107692.0A HK1087335A1 (en) 2003-01-30 2006-07-10 Survivin-derived peptides and use thereof
HK09105575.3A HK1126668A1 (en) 2003-01-30 2009-06-22 Survivin-derived peptides and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK09105575.3A HK1126668A1 (en) 2003-01-30 2009-06-22 Survivin-derived peptides and use thereof

Country Status (16)

Country Link
US (4) US7892559B2 (zh)
EP (5) EP2857034B1 (zh)
JP (1) JP5121143B2 (zh)
CN (2) CN1767848B (zh)
AT (3) ATE506962T1 (zh)
AU (1) AU2004208469B2 (zh)
CA (1) CA2513104C (zh)
DE (3) DE602004025059D1 (zh)
EA (1) EA008026B1 (zh)
ES (2) ES2312956T3 (zh)
HK (2) HK1087335A1 (zh)
MX (1) MXPA05008128A (zh)
NO (1) NO333213B1 (zh)
NZ (1) NZ541510A (zh)
PT (3) PT2092938E (zh)
WO (1) WO2004067023A2 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
KR101216655B1 (ko) 2003-11-19 2013-01-02 수르벡 에이피에스 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도
JP4602006B2 (ja) * 2004-06-29 2010-12-22 独立行政法人科学技術振興機構 サバイビン由来のｈｌａ−ａ２４結合性癌抗原ペプチド
US8487076B1 (en) 2005-01-25 2013-07-16 Nec Corporation HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide
AU2011203535B2 (en) * 2005-02-04 2012-10-11 Survac Aps Survivin peptide vaccine
CN103143004A (zh) 2005-02-04 2013-06-12 萨瓦克公司 存活蛋白肽疫苗
AU2011203536B2 (en) * 2005-02-04 2012-11-15 Survac Aps Survivin peptide vaccine
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
CA2694011C (en) * 2007-07-19 2016-01-12 Health Research, Inc. Survivin peptides as cancer vaccines
US8580269B2 (en) 2007-07-19 2013-11-12 Health Research, Inc. Survivin peptides for autoimmune therapies
KR101648146B1 (ko) * 2008-03-31 2016-08-16 텔라 가부시키가이샤 Ｍｈｃ 클래스 ⅱ 분자에 제시되는 서바이빈의 부분 펩타이드 및 그의 용도
EP2119726B2 (en) * 2008-05-14 2017-11-29 Immatics Biotechnologies GmbH Novel and powerful MHC-class II peptides derived from survivin and neurocan
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
WO2011073215A2 (en) 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
NZ609916A (en) 2010-12-14 2015-03-27 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
EP2688904B1 (en) * 2011-03-21 2017-12-27 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
US10640535B2 (en) 2012-05-25 2020-05-05 Agenus Inc. Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies
US9687538B2 (en) 2012-07-10 2017-06-27 Oncotherapy Science, Inc. CDCA1 epitope peptides for Th1 cells and vaccines containing the same
CA2908042C (en) 2013-03-27 2023-01-31 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
RU2729383C2 (ru) * 2013-11-22 2020-08-06 Зэ Борд оф Трастиз оф зэ Юниверсити оф Иллинойс Сконструированные высокоаффинные t-клеточные рецепторы человека
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
EP3242883A4 (en) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
WO2016176761A1 (en) * 2015-05-01 2016-11-10 Immunovaccine Technologies Inc., Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
AU2016355926A1 (en) 2015-11-18 2018-05-31 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:C polynucleotide adjuvant and a lipid-based adjuvant
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
KR102622188B1 (ko) 2016-10-07 2024-01-05 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
WO2018065625A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
WO2018158456A1 (en) 2017-03-03 2018-09-07 Treos Bio Zrt Personalised immunogenic peptide identification platform
JP6993677B2 (ja) * 2017-11-08 2022-01-13 学校法人日本医科大学 犬におけるがんの予防、がんの治療またはがんの転移の予防のためのがんペプチドワクチン
HUE060791T2 (hu) * 2018-04-11 2023-04-28 Enterome S A Antigén peptidek rák megelõzésére és kezelésére
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
EP3883604A4 (en) * 2018-11-19 2022-10-19 ImmunoVaccine Technologies Inc. METHODS OF IMPROVING THE EFFECTIVENESS OF A SURVIVIN THERAPEUTIC AGENT IN THE TREATMENT OF TUMORS
CN111440246B (zh) * 2020-04-16 2022-03-18 成都仕康美生物科技有限公司 靶向HLA-B的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途
CN118076378A (zh) * 2021-09-24 2024-05-24 株式会社车疫苗研究所 包含肿瘤相关抗原衍生肽以及由脂肽和免疫活性物质组成的佐剂的抗癌疫苗组合物及其用途
CN115477686B (zh) * 2022-09-22 2024-01-30 北海黑珍珠海洋生物科技有限公司 一种具有美白功效的珍珠贝活性肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
JP3608788B2 (ja) 1992-08-31 2005-01-12 ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ Ｍａｇｅ−３遺伝子から誘導されてｈｌａ−ａ１により提示される単離されたノナペプチドおよびそれらの用途
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
JP4672092B2 (ja) 1996-11-20 2011-04-20 イェール ユニバーシティ 細胞アポトーシスを阻害するタンパク質であるサービビン（Ｓｕｒｖｉｖｉｎ）、およびその調節
WO1999050637A2 (en) * 1998-03-27 1999-10-07 Ludwig Institute For Cancer Research Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof
CA2323514A1 (en) * 1998-04-01 1999-10-07 Yale University Method for selectively modulating the interactions between survivin and tubulin
WO2000003693A1 (en) 1998-07-14 2000-01-27 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
CA2440773A1 (en) * 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20040210035A1 (en) 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
KR101216655B1 (ko) 2003-11-19 2013-01-02 수르벡 에이피에스 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도

Also Published As

Publication number Publication date
US8318174B2 (en) 2012-11-27
DE602004025059D1 (de) 2010-02-25
AU2004208469A1 (en) 2004-08-12
DE602004016287D1 (de) 2008-10-16
EP2092938B1 (en) 2011-04-27
EA200501206A1 (ru) 2006-02-24
CN101906148A (zh) 2010-12-08
WO2004067023A2 (en) 2004-08-12
EP2359841B1 (en) 2014-11-05
WO2004067023A3 (en) 2004-10-28
ES2339193T3 (es) 2010-05-17
CA2513104C (en) 2012-12-11
NO20053999L (no) 2005-10-28
EP1587532A2 (en) 2005-10-26
EP2359841A2 (en) 2011-08-24
PT2092938E (pt) 2011-06-07
US20070148184A1 (en) 2007-06-28
CN101906148B (zh) 2013-08-28
US20130115216A1 (en) 2013-05-09
CN1767848B (zh) 2010-04-28
DE602004032483D1 (de) 2011-06-09
CA2513104A1 (en) 2004-08-12
EP2005966A1 (en) 2008-12-24
NZ541510A (en) 2008-04-30
PT2005966E (pt) 2010-03-08
MXPA05008128A (es) 2005-12-05
CN1767848A (zh) 2006-05-03
EP2092938A1 (en) 2009-08-26
HK1126668A1 (en) 2009-09-11
NO20053999D0 (no) 2005-08-29
EP1587532B1 (en) 2008-09-03
EP2857034B1 (en) 2017-04-19
ES2312956T3 (es) 2009-03-01
ATE406906T1 (de) 2008-09-15
ATE506962T1 (de) 2011-05-15
US9534030B2 (en) 2017-01-03
JP5121143B2 (ja) 2013-01-16
USRE48522E1 (en) 2021-04-20
AU2004208469B2 (en) 2010-05-13
JP2006517529A (ja) 2006-07-27
EA008026B1 (ru) 2007-02-27
US7892559B2 (en) 2011-02-22
US20040176573A1 (en) 2004-09-09
PT1587532E (pt) 2008-11-25
EP2005966B1 (en) 2010-01-06
ATE454159T1 (de) 2010-01-15
EP2359841A3 (en) 2011-11-23
NO333213B1 (no) 2013-04-08
EP2857034A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
HK1087335A1 (en) Survivin-derived peptides and use thereof
MXPA03001634A (es) Polipeptido tumoral cripto.
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
NO20181511A1 (no) Survivin-avledede peptider og bruken av dem
DE69828791D1 (de) Das antigen ha-1
DE60139150D1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
AR024114A1 (es) Antigeno (c42) asociado a tumores
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
WO2001098339A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
HUP0303523A2 (hu) Csökkentett immunogenitású, módosított inzulin
WO2004011496A3 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
WO2001027276A3 (en) Dna sequences from breast tumor and uses thereof

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240129